nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—CYP2B6—Ifosfamide—testicular cancer	0.0947	0.118	CbGbCtD
Enzalutamide—CYP3A5—Ifosfamide—testicular cancer	0.0746	0.0928	CbGbCtD
Enzalutamide—CYP2C8—Ifosfamide—testicular cancer	0.0717	0.0892	CbGbCtD
Enzalutamide—CYP2C19—Ifosfamide—testicular cancer	0.0602	0.0749	CbGbCtD
Enzalutamide—CYP2C9—Ifosfamide—testicular cancer	0.05	0.0622	CbGbCtD
Enzalutamide—CYP2B6—Cisplatin—testicular cancer	0.0461	0.0573	CbGbCtD
Enzalutamide—ABCB1—Dactinomycin—testicular cancer	0.0411	0.0512	CbGbCtD
Enzalutamide—CYP3A5—Etoposide—testicular cancer	0.0356	0.0444	CbGbCtD
Enzalutamide—CYP2C8—Etoposide—testicular cancer	0.0343	0.0427	CbGbCtD
Enzalutamide—CYP2B6—Doxorubicin—testicular cancer	0.0309	0.0384	CbGbCtD
Enzalutamide—ALB—Methotrexate—testicular cancer	0.0293	0.0365	CbGbCtD
Enzalutamide—CYP3A4—Ifosfamide—testicular cancer	0.0291	0.0362	CbGbCtD
Enzalutamide—AR—scrotum—testicular cancer	0.0262	0.338	CbGeAlD
Enzalutamide—ABCB1—Vinblastine—testicular cancer	0.0258	0.032	CbGbCtD
Enzalutamide—CYP2C9—Cisplatin—testicular cancer	0.0243	0.0303	CbGbCtD
Enzalutamide—CYP2D6—Vinblastine—testicular cancer	0.0243	0.0302	CbGbCtD
Enzalutamide—ABCB1—Cisplatin—testicular cancer	0.0236	0.0294	CbGbCtD
Enzalutamide—ABCB1—Etoposide—testicular cancer	0.0232	0.0289	CbGbCtD
Enzalutamide—AR—seminiferous tubule of testis—testicular cancer	0.0204	0.263	CbGeAlD
Enzalutamide—ABCB1—Doxorubicin—testicular cancer	0.0158	0.0197	CbGbCtD
Enzalutamide—CYP3A4—Vinblastine—testicular cancer	0.0154	0.0192	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—testicular cancer	0.0153	0.0191	CbGbCtD
Enzalutamide—CYP2D6—Doxorubicin—testicular cancer	0.0149	0.0186	CbGbCtD
Enzalutamide—CYP3A4—Etoposide—testicular cancer	0.0139	0.0173	CbGbCtD
Enzalutamide—AR—semen—testicular cancer	0.0113	0.145	CbGeAlD
Enzalutamide—CYP3A4—Doxorubicin—testicular cancer	0.00948	0.0118	CbGbCtD
Enzalutamide—AR—seminal vesicle—testicular cancer	0.00239	0.0308	CbGeAlD
Enzalutamide—AR—gonad—testicular cancer	0.00173	0.0223	CbGeAlD
Enzalutamide—ALB—testis—testicular cancer	0.00143	0.0185	CbGeAlD
Enzalutamide—AR—female gonad—testicular cancer	0.0014	0.0181	CbGeAlD
Enzalutamide—CYP2B6—gonad—testicular cancer	0.00125	0.0161	CbGeAlD
Enzalutamide—AR—testis—testicular cancer	0.00125	0.016	CbGeAlD
Enzalutamide—Sepsis—Ifosfamide—testicular cancer	0.00123	0.0103	CcSEcCtD
Enzalutamide—Pneumonia—Chlorambucil—testicular cancer	0.0012	0.0101	CcSEcCtD
Enzalutamide—Multiple fractures—Methotrexate—testicular cancer	0.00115	0.0097	CcSEcCtD
Enzalutamide—Fracture—Methotrexate—testicular cancer	0.00115	0.0097	CcSEcCtD
Enzalutamide—Amnesia—Ifosfamide—testicular cancer	0.00109	0.00921	CcSEcCtD
Enzalutamide—ALB—lymph node—testicular cancer	0.00104	0.0134	CbGeAlD
Enzalutamide—CYP3A5—female gonad—testicular cancer	0.00103	0.0132	CbGeAlD
Enzalutamide—CYP2C8—testis—testicular cancer	0.00101	0.013	CbGeAlD
Enzalutamide—ABCB1—embryo—testicular cancer	0.000988	0.0127	CbGeAlD
Enzalutamide—Hypoaesthesia—Vinblastine—testicular cancer	0.00098	0.00825	CcSEcCtD
Enzalutamide—Pharyngitis—Vinblastine—testicular cancer	0.000977	0.00823	CcSEcCtD
Enzalutamide—Sepsis—Etoposide—testicular cancer	0.00097	0.00817	CcSEcCtD
Enzalutamide—Amnesia—Cisplatin—testicular cancer	0.000943	0.00794	CcSEcCtD
Enzalutamide—Pneumonia—Bleomycin—testicular cancer	0.000932	0.00784	CcSEcCtD
Enzalutamide—ABCB1—seminal vesicle—testicular cancer	0.000928	0.0119	CbGeAlD
Enzalutamide—Neutropenia—Dactinomycin—testicular cancer	0.000906	0.00763	CcSEcCtD
Enzalutamide—CYP2B6—testis—testicular cancer	0.000904	0.0116	CbGeAlD
Enzalutamide—AR—lymph node—testicular cancer	0.000903	0.0116	CbGeAlD
Enzalutamide—Haematuria—Bleomycin—testicular cancer	0.000883	0.00744	CcSEcCtD
Enzalutamide—Laryngitis—Epirubicin—testicular cancer	0.000869	0.00732	CcSEcCtD
Enzalutamide—Pneumonia—Dactinomycin—testicular cancer	0.000869	0.00732	CcSEcCtD
Enzalutamide—Leukopenia—Chlorambucil—testicular cancer	0.000837	0.00705	CcSEcCtD
Enzalutamide—Hypoaesthesia—Bleomycin—testicular cancer	0.000828	0.00697	CcSEcCtD
Enzalutamide—Pollakiuria—Ifosfamide—testicular cancer	0.00082	0.00691	CcSEcCtD
Enzalutamide—Convulsion—Chlorambucil—testicular cancer	0.000811	0.00682	CcSEcCtD
Enzalutamide—Laryngitis—Doxorubicin—testicular cancer	0.000805	0.00677	CcSEcCtD
Enzalutamide—Pneumonia—Ifosfamide—testicular cancer	0.000796	0.0067	CcSEcCtD
Enzalutamide—Nasopharyngitis—Cisplatin—testicular cancer	0.000792	0.00667	CcSEcCtD
Enzalutamide—Infestation—Ifosfamide—testicular cancer	0.000792	0.00667	CcSEcCtD
Enzalutamide—Infestation NOS—Ifosfamide—testicular cancer	0.000792	0.00667	CcSEcCtD
Enzalutamide—Vertigo—Vinblastine—testicular cancer	0.00077	0.00648	CcSEcCtD
Enzalutamide—Pharyngitis—Dactinomycin—testicular cancer	0.00077	0.00648	CcSEcCtD
Enzalutamide—Leukopenia—Vinblastine—testicular cancer	0.000767	0.00646	CcSEcCtD
Enzalutamide—Infection—Chlorambucil—testicular cancer	0.000759	0.00638	CcSEcCtD
Enzalutamide—CYP2D6—female gonad—testicular cancer	0.000757	0.00975	CbGeAlD
Enzalutamide—Haematuria—Ifosfamide—testicular cancer	0.000755	0.00636	CcSEcCtD
Enzalutamide—Thrombocytopenia—Chlorambucil—testicular cancer	0.000748	0.00629	CcSEcCtD
Enzalutamide—Musculoskeletal stiffness—Methotrexate—testicular cancer	0.000747	0.00628	CcSEcCtD
Enzalutamide—Convulsion—Vinblastine—testicular cancer	0.000743	0.00625	CcSEcCtD
Enzalutamide—Hypertension—Vinblastine—testicular cancer	0.00074	0.00623	CcSEcCtD
Enzalutamide—Urinary tract disorder—Ifosfamide—testicular cancer	0.000702	0.00591	CcSEcCtD
Enzalutamide—Connective tissue disorder—Ifosfamide—testicular cancer	0.000699	0.00588	CcSEcCtD
Enzalutamide—Urethral disorder—Ifosfamide—testicular cancer	0.000697	0.00587	CcSEcCtD
Enzalutamide—Thrombocytopenia—Vinblastine—testicular cancer	0.000685	0.00577	CcSEcCtD
Enzalutamide—CYP2D6—testis—testicular cancer	0.000672	0.00865	CbGeAlD
Enzalutamide—ABCB1—gonad—testicular cancer	0.00067	0.00863	CbGeAlD
Enzalutamide—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000659	0.00555	CcSEcCtD
Enzalutamide—Fatigue—Chlorambucil—testicular cancer	0.000658	0.00554	CcSEcCtD
Enzalutamide—Neutropenia—Etoposide—testicular cancer	0.000656	0.00552	CcSEcCtD
Enzalutamide—Leukopenia—Bleomycin—testicular cancer	0.000648	0.00546	CcSEcCtD
Enzalutamide—Angiopathy—Ifosfamide—testicular cancer	0.000645	0.00543	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Epirubicin—testicular cancer	0.000634	0.00534	CcSEcCtD
Enzalutamide—Pneumonia—Etoposide—testicular cancer	0.000629	0.00529	CcSEcCtD
Enzalutamide—Paraesthesia—Vinblastine—testicular cancer	0.000628	0.00529	CcSEcCtD
Enzalutamide—Infestation NOS—Etoposide—testicular cancer	0.000625	0.00526	CcSEcCtD
Enzalutamide—Infestation—Etoposide—testicular cancer	0.000625	0.00526	CcSEcCtD
Enzalutamide—Mental disorder—Ifosfamide—testicular cancer	0.000623	0.00524	CcSEcCtD
Enzalutamide—Urinary tract disorder—Cisplatin—testicular cancer	0.000605	0.00509	CcSEcCtD
Enzalutamide—Leukopenia—Dactinomycin—testicular cancer	0.000604	0.00509	CcSEcCtD
Enzalutamide—Connective tissue disorder—Cisplatin—testicular cancer	0.000602	0.00507	CcSEcCtD
Enzalutamide—Urethral disorder—Cisplatin—testicular cancer	0.000601	0.00506	CcSEcCtD
Enzalutamide—Infection—Bleomycin—testicular cancer	0.000587	0.00494	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Doxorubicin—testicular cancer	0.000587	0.00494	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—testicular cancer	0.000581	0.00489	CcSEcCtD
Enzalutamide—Thrombocytopenia—Bleomycin—testicular cancer	0.000579	0.00487	CcSEcCtD
Enzalutamide—Hypoaesthesia—Etoposide—testicular cancer	0.000559	0.0047	CcSEcCtD
Enzalutamide—Vertigo—Ifosfamide—testicular cancer	0.000556	0.00468	CcSEcCtD
Enzalutamide—Urinary tract disorder—Etoposide—testicular cancer	0.000554	0.00467	CcSEcCtD
Enzalutamide—Leukopenia—Ifosfamide—testicular cancer	0.000554	0.00466	CcSEcCtD
Enzalutamide—Urethral disorder—Etoposide—testicular cancer	0.00055	0.00463	CcSEcCtD
Enzalutamide—Asthenia—Chlorambucil—testicular cancer	0.000548	0.00461	CcSEcCtD
Enzalutamide—Infection—Dactinomycin—testicular cancer	0.000548	0.00461	CcSEcCtD
Enzalutamide—ABCB1—female gonad—testicular cancer	0.000545	0.00701	CbGeAlD
Enzalutamide—Sepsis—Epirubicin—testicular cancer	0.000544	0.00458	CcSEcCtD
Enzalutamide—Pruritus—Chlorambucil—testicular cancer	0.00054	0.00455	CcSEcCtD
Enzalutamide—Thrombocytopenia—Dactinomycin—testicular cancer	0.00054	0.00454	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000538	0.00453	CcSEcCtD
Enzalutamide—Convulsion—Ifosfamide—testicular cancer	0.000536	0.00451	CcSEcCtD
Enzalutamide—Hypertension—Ifosfamide—testicular cancer	0.000534	0.0045	CcSEcCtD
Enzalutamide—Paraesthesia—Bleomycin—testicular cancer	0.000531	0.00447	CcSEcCtD
Enzalutamide—Arthralgia—Ifosfamide—testicular cancer	0.000527	0.00443	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000523	0.0044	CcSEcCtD
Enzalutamide—Diarrhoea—Chlorambucil—testicular cancer	0.000522	0.0044	CcSEcCtD
Enzalutamide—Angiopathy—Etoposide—testicular cancer	0.000509	0.00429	CcSEcCtD
Enzalutamide—Sepsis—Doxorubicin—testicular cancer	0.000503	0.00424	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000502	0.00423	CcSEcCtD
Enzalutamide—Asthenia—Vinblastine—testicular cancer	0.000502	0.00423	CcSEcCtD
Enzalutamide—Infection—Ifosfamide—testicular cancer	0.000502	0.00422	CcSEcCtD
Enzalutamide—Nervous system disorder—Ifosfamide—testicular cancer	0.000495	0.00417	CcSEcCtD
Enzalutamide—Thrombocytopenia—Ifosfamide—testicular cancer	0.000495	0.00416	CcSEcCtD
Enzalutamide—Skin disorder—Ifosfamide—testicular cancer	0.000491	0.00413	CcSEcCtD
Enzalutamide—Hot flush—Epirubicin—testicular cancer	0.000486	0.00409	CcSEcCtD
Enzalutamide—ABCB1—testis—testicular cancer	0.000483	0.00622	CbGeAlD
Enzalutamide—Menopausal symptoms—Epirubicin—testicular cancer	0.000482	0.00406	CcSEcCtD
Enzalutamide—Diarrhoea—Vinblastine—testicular cancer	0.000479	0.00403	CcSEcCtD
Enzalutamide—Leukopenia—Cisplatin—testicular cancer	0.000478	0.00402	CcSEcCtD
Enzalutamide—Fatigue—Dactinomycin—testicular cancer	0.000475	0.004	CcSEcCtD
Enzalutamide—Back pain—Etoposide—testicular cancer	0.000473	0.00398	CcSEcCtD
Enzalutamide—Dizziness—Vinblastine—testicular cancer	0.000463	0.00389	CcSEcCtD
Enzalutamide—Convulsion—Cisplatin—testicular cancer	0.000462	0.00389	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00046	0.00387	CcSEcCtD
Enzalutamide—Paraesthesia—Ifosfamide—testicular cancer	0.000454	0.00382	CcSEcCtD
Enzalutamide—Anxiety—Cisplatin—testicular cancer	0.000453	0.00381	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000451	0.0038	CcSEcCtD
Enzalutamide—Hot flush—Doxorubicin—testicular cancer	0.00045	0.00379	CcSEcCtD
Enzalutamide—Menopausal symptoms—Doxorubicin—testicular cancer	0.000446	0.00375	CcSEcCtD
Enzalutamide—Vertigo—Etoposide—testicular cancer	0.000439	0.0037	CcSEcCtD
Enzalutamide—Headache—Vinblastine—testicular cancer	0.000438	0.00369	CcSEcCtD
Enzalutamide—Leukopenia—Etoposide—testicular cancer	0.000437	0.00368	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000436	0.00367	CcSEcCtD
Enzalutamide—Fatigue—Ifosfamide—testicular cancer	0.000435	0.00366	CcSEcCtD
Enzalutamide—Infection—Cisplatin—testicular cancer	0.000433	0.00364	CcSEcCtD
Enzalutamide—Nervous system disorder—Cisplatin—testicular cancer	0.000427	0.00359	CcSEcCtD
Enzalutamide—Thrombocytopenia—Cisplatin—testicular cancer	0.000426	0.00359	CcSEcCtD
Enzalutamide—Asthenia—Bleomycin—testicular cancer	0.000424	0.00357	CcSEcCtD
Enzalutamide—Convulsion—Etoposide—testicular cancer	0.000423	0.00356	CcSEcCtD
Enzalutamide—Skin disorder—Cisplatin—testicular cancer	0.000423	0.00356	CcSEcCtD
Enzalutamide—Hypertension—Etoposide—testicular cancer	0.000422	0.00355	CcSEcCtD
Enzalutamide—Pruritus—Bleomycin—testicular cancer	0.000418	0.00352	CcSEcCtD
Enzalutamide—Dry skin—Epirubicin—testicular cancer	0.000417	0.00351	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000413	0.00348	CcSEcCtD
Enzalutamide—Nasopharyngitis—Epirubicin—testicular cancer	0.000407	0.00342	CcSEcCtD
Enzalutamide—Muscular weakness—Epirubicin—testicular cancer	0.000401	0.00338	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000397	0.00334	CcSEcCtD
Enzalutamide—Infection—Etoposide—testicular cancer	0.000396	0.00334	CcSEcCtD
Enzalutamide—Asthenia—Dactinomycin—testicular cancer	0.000395	0.00333	CcSEcCtD
Enzalutamide—Neutropenia—Methotrexate—testicular cancer	0.000393	0.00331	CcSEcCtD
Enzalutamide—Paraesthesia—Cisplatin—testicular cancer	0.000391	0.00329	CcSEcCtD
Enzalutamide—Thrombocytopenia—Etoposide—testicular cancer	0.000391	0.00329	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Methotrexate—testicular cancer	0.00039	0.00329	CcSEcCtD
Enzalutamide—Skin disorder—Etoposide—testicular cancer	0.000387	0.00326	CcSEcCtD
Enzalutamide—Dry skin—Doxorubicin—testicular cancer	0.000386	0.00325	CcSEcCtD
Enzalutamide—Bronchitis—Epirubicin—testicular cancer	0.000378	0.00318	CcSEcCtD
Enzalutamide—Diarrhoea—Dactinomycin—testicular cancer	0.000377	0.00317	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—testicular cancer	0.000377	0.00317	CcSEcCtD
Enzalutamide—Nasopharyngitis—Doxorubicin—testicular cancer	0.000376	0.00317	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000376	0.00316	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—testicular cancer	0.000375	0.00315	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—testicular cancer	0.000375	0.00315	CcSEcCtD
Enzalutamide—Muscular weakness—Doxorubicin—testicular cancer	0.000371	0.00312	CcSEcCtD
Enzalutamide—Neutropenia—Epirubicin—testicular cancer	0.000368	0.00309	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000365	0.00308	CcSEcCtD
Enzalutamide—Pollakiuria—Epirubicin—testicular cancer	0.000363	0.00306	CcSEcCtD
Enzalutamide—Asthenia—Ifosfamide—testicular cancer	0.000362	0.00305	CcSEcCtD
Enzalutamide—Paraesthesia—Etoposide—testicular cancer	0.000358	0.00301	CcSEcCtD
Enzalutamide—Pruritus—Ifosfamide—testicular cancer	0.000357	0.00301	CcSEcCtD
Enzalutamide—Haematuria—Methotrexate—testicular cancer	0.000357	0.00301	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—testicular cancer	0.000353	0.00297	CcSEcCtD
Enzalutamide—Pneumonia—Epirubicin—testicular cancer	0.000353	0.00297	CcSEcCtD
Enzalutamide—Infestation NOS—Epirubicin—testicular cancer	0.000351	0.00295	CcSEcCtD
Enzalutamide—Infestation—Epirubicin—testicular cancer	0.000351	0.00295	CcSEcCtD
Enzalutamide—ABCB1—lymph node—testicular cancer	0.00035	0.00451	CbGeAlD
Enzalutamide—Bronchitis—Doxorubicin—testicular cancer	0.00035	0.00294	CcSEcCtD
Enzalutamide—Diarrhoea—Ifosfamide—testicular cancer	0.000346	0.00291	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Etoposide—testicular cancer	0.000344	0.0029	CcSEcCtD
Enzalutamide—Fatigue—Etoposide—testicular cancer	0.000344	0.00289	CcSEcCtD
Enzalutamide—Neutropenia—Doxorubicin—testicular cancer	0.00034	0.00286	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000338	0.00285	CcSEcCtD
Enzalutamide—Pollakiuria—Doxorubicin—testicular cancer	0.000336	0.00283	CcSEcCtD
Enzalutamide—Haematuria—Epirubicin—testicular cancer	0.000334	0.00281	CcSEcCtD
Enzalutamide—Dizziness—Ifosfamide—testicular cancer	0.000334	0.00281	CcSEcCtD
Enzalutamide—Pharyngitis—Methotrexate—testicular cancer	0.000334	0.00281	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—testicular cancer	0.000332	0.0028	CcSEcCtD
Enzalutamide—Epistaxis—Epirubicin—testicular cancer	0.000331	0.00278	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—testicular cancer	0.00033	0.00277	CcSEcCtD
Enzalutamide—Sinusitis—Epirubicin—testicular cancer	0.000329	0.00277	CcSEcCtD
Enzalutamide—Pneumonia—Doxorubicin—testicular cancer	0.000326	0.00275	CcSEcCtD
Enzalutamide—Infestation—Doxorubicin—testicular cancer	0.000324	0.00273	CcSEcCtD
Enzalutamide—Infestation NOS—Doxorubicin—testicular cancer	0.000324	0.00273	CcSEcCtD
Enzalutamide—Rhinitis—Epirubicin—testicular cancer	0.000316	0.00266	CcSEcCtD
Enzalutamide—Hypoaesthesia—Epirubicin—testicular cancer	0.000313	0.00264	CcSEcCtD
Enzalutamide—Asthenia—Cisplatin—testicular cancer	0.000312	0.00263	CcSEcCtD
Enzalutamide—Pharyngitis—Epirubicin—testicular cancer	0.000312	0.00263	CcSEcCtD
Enzalutamide—Urinary tract disorder—Epirubicin—testicular cancer	0.000311	0.00262	CcSEcCtD
Enzalutamide—Oedema peripheral—Epirubicin—testicular cancer	0.00031	0.00261	CcSEcCtD
Enzalutamide—Haematuria—Doxorubicin—testicular cancer	0.000309	0.0026	CcSEcCtD
Enzalutamide—Connective tissue disorder—Epirubicin—testicular cancer	0.000309	0.0026	CcSEcCtD
Enzalutamide—Urethral disorder—Epirubicin—testicular cancer	0.000309	0.0026	CcSEcCtD
Enzalutamide—Epistaxis—Doxorubicin—testicular cancer	0.000306	0.00258	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—testicular cancer	0.000305	0.00257	CcSEcCtD
Enzalutamide—Sinusitis—Doxorubicin—testicular cancer	0.000304	0.00256	CcSEcCtD
Enzalutamide—Diarrhoea—Cisplatin—testicular cancer	0.000298	0.00251	CcSEcCtD
Enzalutamide—Mental disorder—Methotrexate—testicular cancer	0.000295	0.00248	CcSEcCtD
Enzalutamide—Rhinitis—Doxorubicin—testicular cancer	0.000292	0.00246	CcSEcCtD
Enzalutamide—Hypoaesthesia—Doxorubicin—testicular cancer	0.00029	0.00244	CcSEcCtD
Enzalutamide—Pharyngitis—Doxorubicin—testicular cancer	0.000289	0.00243	CcSEcCtD
Enzalutamide—Urinary tract disorder—Doxorubicin—testicular cancer	0.000288	0.00242	CcSEcCtD
Enzalutamide—Oedema peripheral—Doxorubicin—testicular cancer	0.000287	0.00241	CcSEcCtD
Enzalutamide—Asthenia—Etoposide—testicular cancer	0.000286	0.00241	CcSEcCtD
Enzalutamide—Connective tissue disorder—Doxorubicin—testicular cancer	0.000286	0.00241	CcSEcCtD
Enzalutamide—Angiopathy—Epirubicin—testicular cancer	0.000286	0.0024	CcSEcCtD
Enzalutamide—Urethral disorder—Doxorubicin—testicular cancer	0.000285	0.0024	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—testicular cancer	0.000283	0.00238	CcSEcCtD
Enzalutamide—Pruritus—Etoposide—testicular cancer	0.000282	0.00238	CcSEcCtD
Enzalutamide—Mental disorder—Epirubicin—testicular cancer	0.000276	0.00232	CcSEcCtD
Enzalutamide—Diarrhoea—Etoposide—testicular cancer	0.000273	0.0023	CcSEcCtD
Enzalutamide—Back pain—Epirubicin—testicular cancer	0.000265	0.00223	CcSEcCtD
Enzalutamide—Angiopathy—Doxorubicin—testicular cancer	0.000264	0.00222	CcSEcCtD
Enzalutamide—Dizziness—Etoposide—testicular cancer	0.000264	0.00222	CcSEcCtD
Enzalutamide—Vertigo—Methotrexate—testicular cancer	0.000263	0.00221	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—testicular cancer	0.000262	0.00221	CcSEcCtD
Enzalutamide—Mental disorder—Doxorubicin—testicular cancer	0.000255	0.00215	CcSEcCtD
Enzalutamide—Convulsion—Methotrexate—testicular cancer	0.000254	0.00213	CcSEcCtD
Enzalutamide—Headache—Etoposide—testicular cancer	0.00025	0.0021	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—testicular cancer	0.000249	0.0021	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000248	0.00208	CcSEcCtD
Enzalutamide—Vertigo—Epirubicin—testicular cancer	0.000246	0.00207	CcSEcCtD
Enzalutamide—Leukopenia—Epirubicin—testicular cancer	0.000245	0.00206	CcSEcCtD
Enzalutamide—Back pain—Doxorubicin—testicular cancer	0.000245	0.00206	CcSEcCtD
Enzalutamide—Convulsion—Epirubicin—testicular cancer	0.000237	0.002	CcSEcCtD
Enzalutamide—Infection—Methotrexate—testicular cancer	0.000237	0.002	CcSEcCtD
Enzalutamide—Hypertension—Epirubicin—testicular cancer	0.000237	0.00199	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—testicular cancer	0.000234	0.00197	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—testicular cancer	0.000234	0.00197	CcSEcCtD
Enzalutamide—Arthralgia—Epirubicin—testicular cancer	0.000233	0.00196	CcSEcCtD
Enzalutamide—Anxiety—Epirubicin—testicular cancer	0.000232	0.00196	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—testicular cancer	0.000232	0.00195	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000232	0.00195	CcSEcCtD
Enzalutamide—Vertigo—Doxorubicin—testicular cancer	0.000228	0.00192	CcSEcCtD
Enzalutamide—Leukopenia—Doxorubicin—testicular cancer	0.000227	0.00191	CcSEcCtD
Enzalutamide—Infection—Epirubicin—testicular cancer	0.000222	0.00187	CcSEcCtD
Enzalutamide—Convulsion—Doxorubicin—testicular cancer	0.00022	0.00185	CcSEcCtD
Enzalutamide—Nervous system disorder—Epirubicin—testicular cancer	0.000219	0.00185	CcSEcCtD
Enzalutamide—Thrombocytopenia—Epirubicin—testicular cancer	0.000219	0.00184	CcSEcCtD
Enzalutamide—Hypertension—Doxorubicin—testicular cancer	0.000219	0.00184	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000218	0.00183	CcSEcCtD
Enzalutamide—Skin disorder—Epirubicin—testicular cancer	0.000217	0.00183	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—testicular cancer	0.000216	0.00182	CcSEcCtD
Enzalutamide—Arthralgia—Doxorubicin—testicular cancer	0.000216	0.00182	CcSEcCtD
Enzalutamide—Anxiety—Doxorubicin—testicular cancer	0.000215	0.00181	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—testicular cancer	0.000215	0.00181	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000214	0.0018	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000206	0.00174	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—testicular cancer	0.000206	0.00173	CcSEcCtD
Enzalutamide—Infection—Doxorubicin—testicular cancer	0.000206	0.00173	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000204	0.00171	CcSEcCtD
Enzalutamide—Nervous system disorder—Doxorubicin—testicular cancer	0.000203	0.00171	CcSEcCtD
Enzalutamide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000203	0.0017	CcSEcCtD
Enzalutamide—Insomnia—Epirubicin—testicular cancer	0.000202	0.0017	CcSEcCtD
Enzalutamide—Skin disorder—Doxorubicin—testicular cancer	0.000201	0.00169	CcSEcCtD
Enzalutamide—Paraesthesia—Epirubicin—testicular cancer	0.000201	0.00169	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000193	0.00162	CcSEcCtD
Enzalutamide—Fatigue—Epirubicin—testicular cancer	0.000193	0.00162	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000188	0.00159	CcSEcCtD
Enzalutamide—Insomnia—Doxorubicin—testicular cancer	0.000187	0.00158	CcSEcCtD
Enzalutamide—Paraesthesia—Doxorubicin—testicular cancer	0.000186	0.00156	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000179	0.0015	CcSEcCtD
Enzalutamide—Fatigue—Doxorubicin—testicular cancer	0.000178	0.0015	CcSEcCtD
Enzalutamide—Asthenia—Methotrexate—testicular cancer	0.000171	0.00144	CcSEcCtD
Enzalutamide—Pruritus—Methotrexate—testicular cancer	0.000169	0.00142	CcSEcCtD
Enzalutamide—Diarrhoea—Methotrexate—testicular cancer	0.000163	0.00138	CcSEcCtD
Enzalutamide—Asthenia—Epirubicin—testicular cancer	0.00016	0.00135	CcSEcCtD
Enzalutamide—Pruritus—Epirubicin—testicular cancer	0.000158	0.00133	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—testicular cancer	0.000158	0.00133	CcSEcCtD
Enzalutamide—Diarrhoea—Epirubicin—testicular cancer	0.000153	0.00129	CcSEcCtD
Enzalutamide—Headache—Methotrexate—testicular cancer	0.00015	0.00126	CcSEcCtD
Enzalutamide—Asthenia—Doxorubicin—testicular cancer	0.000148	0.00125	CcSEcCtD
Enzalutamide—Dizziness—Epirubicin—testicular cancer	0.000148	0.00124	CcSEcCtD
Enzalutamide—Pruritus—Doxorubicin—testicular cancer	0.000146	0.00123	CcSEcCtD
Enzalutamide—Diarrhoea—Doxorubicin—testicular cancer	0.000142	0.00119	CcSEcCtD
Enzalutamide—Headache—Epirubicin—testicular cancer	0.00014	0.00118	CcSEcCtD
Enzalutamide—Dizziness—Doxorubicin—testicular cancer	0.000137	0.00115	CcSEcCtD
Enzalutamide—Headache—Doxorubicin—testicular cancer	0.00013	0.00109	CcSEcCtD
